Wedbush Reiterates Outperform on Prime Medicine, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten reiterates an Outperform rating on Prime Medicine (NASDAQ:PRME) and maintains a $12 price target.
April 23, 2024 | 5:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten reiterates an Outperform rating on Prime Medicine and maintains a $12 price target.
The reiteration of an Outperform rating and the maintenance of a $12 price target by a reputable analyst like David Nierengarten from Wedbush could signal a strong vote of confidence in Prime Medicine's stock. This endorsement may positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100